Zachary Simmons

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1712656/publications.pdf

Version: 2024-02-01

99 papers	4,642 citations	117453 34 h-index	114278 63 g-index
106 all docs	106 docs citations	106 times ranked	5697 citing authors

#	Article	IF	Citations
1	Amyotrophic lateral sclerosis. Nature Reviews Disease Primers, 2017, 3, 17071.	18.1	885
2	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
3	Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nature Genetics, 1997, 16, 407-409.	9.4	205
4	<scp>COVIDâ€19â€“associated Guillainâ€BarrÃ©</scp> syndrome: The early pandemic experience. Muscle and Nerve, 2020, 62, 485-491.	1.0	196
5	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	0.9	118
6	Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. Journal of the Neurological Sciences, 2004, 227, 27-33.	0.3	114
7	Update on diabetic neuropathy. Current Opinion in Neurology, 2002, 15, 595-603.	1.8	99
8	Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 2012, 46, 9-25.	1.0	96
9	Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 413-418.	0.9	95
10	Management Strategies for Patients With Amyotrophic Lateral Sclerosis From Diagnosis Through Death. Neurologist, 2005, 11, 257-270.	0.4	92
11	Isaacs syndrome: A review. Muscle and Nerve, 2015, 52, 5-12.	1.0	88
12	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
13	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.5	72
14	Pseudobulbar affect: prevalence and management. Therapeutics and Clinical Risk Management, 2013, 9, 483.	0.9	70
15	Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. , 1997, 20, 1569-1575.		68
16	Low diagnostic yield of sural nerve biopsy in patients with peripheral neuropathy and primary amyloidosis. Journal of the Neurological Sciences, 1993, 120, 60-63.	0.3	67
17	Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 555-561.	1.1	67
18	Patient-Perceived Outcomes and Quality of Life in ALS. Neurotherapeutics, 2015, 12, 394-402.	2.1	63

#	Article	IF	Citations
19	Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Muscle and Nerve, 2002, 26, 141-144.	1.0	62
20	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. , 1997, 20, 1008-1015.		59
21	Localized hypertrophic neuropathy: Magnetic resonance imaging findings and long-term follow-up. , 1999, 22, 28-36.		59
22	A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology, 2006, 67, 2070-2072.	1.5	55
23	Unexpected similarities between C9ORF72 and sporadic forms of ALS/FTD suggest a common disease mechanism. ELife, 2018, 7, .	2.8	53
24	Religiousness is related to quality of life in patients with ALS. Neurology, 2003, 60, 1527-1529.	1.5	51
25	A Qualitative Study of Multidisciplinary ALS Clinic Use in the United States. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 55-61.	1.1	50
26	Verbal communication impacts quality of life in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 179-183.	1.1	49
27	Respiratory systems abnormalities and clinical milestones for patients with amyotrophic lateral sclerosis with emphasis upon survival. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 36-41.	2.3	47
28	Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 1236.	4.5	46
29	Factors supporting quality of life over time for individuals with amyotrophic lateral sclerosis: the role of positive self-perception and religiosity. Annals of Behavioral Medicine, 2004, 28, 119-125.	1.7	44
30	The SEIQoL-DW for assessing quality of life in ALS: Strengths and limitations. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 456-462.	2.3	44
31	ULTRASOUND IN THE DIAGNOSIS AND MONITORING OF AMYOTROPHIC LATERAL SCLEROSIS: A REVIEW. Muscle and Nerve, 2019, 60, 114-123.	1.0	43
32	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.1	42
33	Amyotrophic lateral sclerosis care and research in the United States during the <scp>COVID</scp>â€19 pandemic: Challenges and opportunities. Muscle and Nerve, 2020, 62, 182-186.	1.0	42
34	Muscle biopsy in the evaluation of patients with modestly elevated creatine kinase levels. Muscle and Nerve, 2003, 27, 242-244.	1.0	39
35	The Use of Telehealth to Enhance Care in ALS and other Neuromuscular Disorders. Muscle and Nerve, 2020, 61, 682-691.	1.0	39
36	Psychological health in patients with ALS is maintained as physical function declines. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 290-296.	2.3	37

#	Article	IF	Citations
37	Patient-reported problematic symptoms in an ALS treatment trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 198-205.	1.1	37
38	Reproducibility of motor unit number estimation in individual subjects. Muscle and Nerve, 2001, 24, 467-473.	1.0	35
39	Problem solving skills predict quality of life and psychological morbidity in ALS caregivers. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 147-153.	2.3	35
40	The potential of psychological interventions to improve quality of life and mood in muscle disorders. Muscle and Nerve, 2015, 52, 131-136.	1.0	35
41	Psychological morbidity in ALS: The importance of psychological assessment beyond depression alone. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 351-358.	2.3	32
42	The Neuromuscular Manifestations of Amyloidosis. Journal of Clinical Neuromuscular Disease, 2010, 11, 145-157.	0.3	31
43	Pain in amyotrophic lateral sclerosis: Patient and physician perspectives and practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 21-29.	1.1	31
44	Evaluation of remote pulmonary function testing in motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 348-355.	1.1	28
45	Understanding the needs of people with ALS: a national survey of patients and caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 355-363.	1.1	27
46	Tocilizumab is safe and tolerable and reduces <scp>C</scp>â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320.	1.0	27
47	H63D HFE genotype accelerates disease progression in animal models of amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2413-2426.	1.8	26
48	Advance care planning for patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 388-396.	1.1	26
49	Telemedicine to innovate amyotrophic lateral sclerosis multidisciplinary care: The time has come. Muscle and Nerve, 2019, 59, 3-5.	1.0	25
50	Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle and Nerve, 2020, 62, 321-326.	1.0	24
51	Non-invasive ventilation and gastrostomy may not impact overall quality of life in patients with ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 55-58.	2.3	23
52	Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 473-477.	1.1	23
53	Statins accelerate disease progression and shorten survival in SOD1^{G93A} mice. Muscle and Nerve, 2016, 54, 284-291.	1.0	23
54	Amyotrophic lateral sclerosisâ€“specific quality of lifeâ€“short form (ALSSQOLâ€SF): A brief, reliable, and valid version of the ALSSQOLâ€R. Muscle and Nerve, 2018, 58, 646-654.	1.0	21

#	Article	IF	Citations
55	Electrodiagnosis of Brachial Plexopathies and Proximal Upper Extremity Neuropathies. Physical Medicine and Rehabilitation Clinics of North America, 2013, 24, 13-32.	0.7	20
56	Lawful physician-hastened death. Neurology, 2018, 90, 420-422.	1.5	19
57	Multidisciplinary ALS clinics in the USA: A comparison of those who attend and those who do not. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 196-201.	1.1	17
58	Primary Lateral Sclerosis and Early Upper Motor Neuron Disease. Journal of Clinical Neuromuscular Disease, 2016, 17, 99-105.	0.3	17
59	Primary lateral sclerosis (PLS) functional rating scale: PLSâ€specific clinimetric scale. Muscle and Nerve, 2020, 61, 163-172.	1.0	17
60	Rehabilitation of motor neuron disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 110, 483-498.	1.0	15
61	The role of mental health and self-efficacy in the pain experience of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 206-212.	1.1	15
62	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	1.0	13
63	Sporadic Inclusion Body Myositis and Hereditary Inclusion Body Myopathy. Journal of Clinical Neuromuscular Disease, 2002, 3, 122-132.	0.3	12
64	An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 116-127.	1.1	12
65	Ethical Considerations in Dementia Diagnosis and Care. Neurology, 2021, 97, 80-89.	1.5	12
66	Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 167-172.	1.1	11
67	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.1	11
68	Variation of calculated ulnar motor conduction velocity across the elbow with body mass index. , 1997, 20, 1607-1608.		10
69	Compliance with recommendations made in a multidisciplinary ALS clinic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 30-37.	1.1	9
70	Can we eliminate placebo in ALS clinical Trials?. Muscle and Nerve, 2009, 39, 861-865.	1.0	8
71	The P300 â€˜faceâ€™ speller is resistant to cognitive decline in ALS. Brain-Computer Interfaces, 2017, 4, 225-235.	0.9	8
72	Hydration measured by doubly labeled water in ALS and its effects on survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 220-231.	1.1	8

#	Article	IF	Citations
73	Inertial sensing of step kinematics in ambulatory patients with ALS and related motor neuron diseases. Journal of Medical Engineering and Technology, 2021, 45, 486-493.	0.8	6
74	Symptom management in amyotrophic lateral sclerosis: We can do better. Muscle and Nerve, 2018, 57, 1-3.	1.0	5
75	Ethical Considerations in Neurogenetic Testing. Seminars in Neurology, 2018, 38, 505-514.	0.5	5
76	VALUESâ€: a national multicenter study of regional and gender differences in frontotemporal disease in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2012, 2, 325-336.	1.2	4
77	Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. Muscle and Nerve, 2016, 54, 997-1006.	1.0	4
78	Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle and Nerve, 1997, 20, 1008-1015.	1.0	3
79	So many submissionsâ€¦so little space. Muscle and Nerve, 2017, 55, 299-300.	1.0	2
80	Telemedicine for the Care of Neuromuscular Disorders. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	2
81	Terminology in Neuromuscular Electrodiagnostic Medicine and Ultrasound: Time for an Update. Muscle and Nerve, 2020, 62, 1-1.	1.0	2
82	In defense of the AAN position on lawful physician-hastened death. Neurology, 2020, 94, 641-643.	1.5	2
83	Palliative specialists for patients with <scp>ALS</scp>: Making best use of a limited resource. Muscle and Nerve, 2021, 63, 790-792.	1.0	2
84	Ten years of riluzole use in a tertiary ALS clinic. Muscle and Nerve, 2022, 65, 659-666.	1.0	2
85	Treatment of Diabetic Neuropathy. , 0, , 555-576.		1
86	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2010, 11, 223-228.	0.3	1
87	Loss and well-being in ALS: A different perspective on the challenge. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 163-164.	1.1	1
88	Muscle & nervejoins the â€œApp Worldâ€• Muscle and Nerve, 2016, 53, 1-2.	1.0	1
89	Article submission: The scope of muscle & nerve. Muscle and Nerve, 2017, 55, 615-616.	1.0	1
90	Expansion of C9ORF72 in amyotrophic lateral sclerosis correlates with brain-computer interface performance. Scientific Reports, 2017, 7, 8875.	1.6	1

#	Article	IF	Citations
91	Physicianâ€hastened death in <scp>California</scp> for patients with amyotrophic lateral sclerosis: Part of a bigger picture. Muscle and Nerve, 2021, 64, 381-384.	1.0	1
92	What's in the Literature?. Journal of Clinical Neuromuscular Disease, 2012, 13, 162-167.	0.3	0
93	Neuromuscular images: A picture can be worth more than a thousand words. Muscle and Nerve, 2017, 56, 1-1.	1.0	0
94	A new editor: Changes in Muscle & Nerve. Muscle and Nerve, 2017, 55, 1-2.	1.0	0
95	Goodbye to neuromuscular images. Muscle and Nerve, 2018, 57, 167-167.	1.0	0
96	Guidelines for Authors: A view from the Editor's desk. Muscle and Nerve, 2018, 59, 147-148.	1.0	0
97	Changing with the times. Muscle and Nerve, 2019, 60, 343-344.	1.0	0
98	What's New at Muscle & Nerve?. Muscle and Nerve, 2020, 62, 152-153.	1.0	0
99	Laryngospasm: A frequently underrecognized symptom in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, , .	1.0	0